First Tracks Biotherapeutics - Asset Resilience Ratio
First Tracks Biotherapeutics (TRAX) has an Asset Resilience Ratio of 0.00% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does First Tracks Biotherapeutics carry for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2025)
This chart shows how First Tracks Biotherapeutics's Asset Resilience Ratio has changed over time. See how financially flexible is First Tracks Biotherapeutics to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down First Tracks Biotherapeutics's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see First Tracks Biotherapeutics balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: First Tracks Biotherapeutics maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
First Tracks Biotherapeutics Industry Peers by Asset Resilience Ratio
Compare First Tracks Biotherapeutics's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 16.06% |
|
Dyne Therapeutics Inc
NASDAQ:DYN |
Biotechnology | 20.28% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Recursion Pharmaceuticals Inc
NASDAQ:RXRX |
Biotechnology | 0.00% |
|
LegoChem Biosciences Inc
KQ:141080 |
Biotechnology | 55.88% |
Annual Asset Resilience Ratio for First Tracks Biotherapeutics (2023–2025)
The table below shows the annual Asset Resilience Ratio data for First Tracks Biotherapeutics.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 22.22% | $73.44 Million | $330.55 Million | -37.14pp |
| 2024-12-31 | 59.36% | $262.29 Million | $441.89 Million | -20.56pp |
| 2023-12-31 | 79.92% | $354.94 Million | $444.11 Million | -- |
About First Tracks Biotherapeutics
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in bo… Read more